Previous 10 | Next 10 |
TEL AVIV, Israel , Nov. 26, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will host an investor breakfast meeting on Thursday, December 5, 2019 at the Convene Conferen...
BioLineRx Ltd. (BLRX) Q3 2019 Results Earnings Conference Call November 11, 2019, 10:00 AM ET Company Participants Timothy McCarthy - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical and Medical Affairs Conference Call Participants Joe ...
BioLineRx ( BLRX ) Q3 results : Revenues: $0; R&D Expense: $5.6M (+12.0%); SG&A: $1.1M (-8.3%); Net loss: ($3.9M) (+38.1%); loss/share: ($0.03) (+50.0%); Quick Assets: $30.1M (-0.3%); CF Ops: ($17.2M) (+9.9%). More news on: BioLineRx Ltd., Healthcare stocks news, Earnings new...
TEL AVIV, Israel , Nov. 11, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended September 30, 2019 and provides a corporate update. High...
TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2019 on Monday, November ...
Thinly traded nano cap BioLineRx Ltd. ( BLRX -6.8% ) is down on a 10x surge in volume, albeit on turnover of only 527K shares, in apparent reaction to results from an open-label Phase 2b clinical trial evaluating the combination of BL-8040 and Merck's ( MRK -0.8% ) Keytruda (pembroli...
FlexShopper (NASDAQ: FPAY ) +36% on Q3 results . More news on: FlexShopper, Inc., EverQuote, Inc., Inovio Pharmaceuticals, Inc., Stocks on the move, Read more ...
TEL AVIV , Israel , Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today results of a Phase 2b trial assessing the efficacy of BL-8040 in combination with KEYTRUDA ® (pe...
TEL AVIV , Israel , Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further elucidating the mechanism of action of BL-8040 in combination with an anti P...
TEL AVIV , Israel , Oct. 31, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will deliver the following poster presentations at the Society for Immunotherapy of Cancer (...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...